Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

TENOFOVIR ALAFENAMIDE

All products: Limited Use (codes 517, 518, 519, 520, 521)

Other products in the same Health Canada class (J05AF) — coverage varies; not interchangeable

  • Abacavir (Ziagen): general benefit
  • Lamivudine (3tc): general benefit, Limited Use 502, 503, 504, Not a benefit
  • Entecavir (Baraclude): limited Use 505, 506, 507, 508
  • Tenofovir disoproxil (Viread): limited Use 517, 518, 519, 520, 521, 522
  • Adefovir dipivoxil (Hepsera): not a benefit
  • Zidovudine (Retrovir): not a benefit

48 more in the class list below

Vemlidy · DIN 02464241 · 25mg · tablet

Limited Use — Reason for Use code 517, 518, 519, 520, 521 requiredMarketed · checked 2026-09-19
StatusLimited Use — Reason for Use code 517, 518, 519, 520, 521 required
Write on scriptLU code 517, 518, 519, 520, 521 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 517, 518, 519, 520, 521
Reason for Use code 517 Confirmed chronic Hepatitis B infection in persons with - HBV DNA greater than or equal to 1000 IU/mL AND - ALT levels greater than ULN OR - Evidence of fibrosis OR - Documented evidence of cirrhosis Coverage limit: LU Authorization Period: 1 year Reason for Use code 518 For patients with chronic Hepatitis B infection who have a contraindication, intolerance or inadequate response to one or more of the following: lamivudine, entecavir, adefovir or telbivudine. Coverage limit: LU Authorization Period: 1 year Reason for Use code 519 Patient is pregnant (2nd trimester or later) with HBV DNA greater than 1,000,000 IU/mL. Coverage limit: LU Authorization Period: 1 year Reason for Use code 520 Patients with chronic Hepatitis B infection currently receiving treatment with tenofovir and requires treatment continuation. Coverage limit: LU Authorization Period: 1 year Reason for Use code 521 Patients with chronic Hepatitis B infection who are scheduled to undergo chemotherapy or significant immunosuppressive treatment. Coverage limit: LU Authorization Period: 1 year
No interchangeable product listed in the Ontario extract
Vemlidy · DIN 02464241 Manufacturer: Gilead Sciences Canada, Inc.; listing date 2026-01-30 Health Canada: Marketed since 2017-06-20 · brand VEMLIDY · ATC J05AF13 TENOFOVIR ALAFENAMIDE · form Tablet · route Oral · ingredients TENOFOVIR ALAFENAMIDE (TENOFOVIR ALAFENAMIDE HEMIFUMARATE) 25 MG · company Gilead sciences canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Vemlidy: Formulary list price $19.5537/unit (unit not stated in source; not the patient's cost)

Ministry pays: $19.5537 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95241 · Verify on the e-Formulary ↗ (DIN 02464241)

Source record
DIN 02464241: Vemlidy Raw flags: sec12=Y, sec3=Y Item: 081800422; group id 112; item number 0194; lccId 00425; manufacturer id GIL Source form: Tab; strength: 25mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $19.5537; ministry $19.5537 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02464241 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95241
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (08:18 Antivirals) and how they are covered

Matched class: 08:18 Antivirals

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ABACAVIR & LAMIVUDINE & ZIDOVUDINE, ABACAVIR SULFATE, ABACAVIR SULFATE & LAMIVUDINE, BICTEGRAVIR SODIUM/EMTRICITABINE/TENOFOVIR ALAFENAMIDE HEMIFUMARATE, CABOTEGRAVIR, CABOTEGRAVIR & RILPIVIRINE, COBICISTAT & ELVITEGRAVIR & EMTRICITABINE & TENOFOVIR DISOPROXIL FUMARATE, DARUNAVIR & COBICISTAT, DARUNAVIR & COBICISTAT & EMTRICITABINE & TENOFOVIR ALAFENAMIDE, DELAVIRDINE MESYLATE, DOLUTEGRAVIR, DOLUTEGRAVIR & ABACAVIR & LAMIVUDINE, DOLUTEGRAVIR & RILPIVIRINE, DOLUTEGRAVIR SODIUM/LAMIVUDINE, DORAVIRINE, DORAVIRINE/LAMIVUDINE/TENOFOVIR DISOPROXIL FUMARATE, EFAVIRENZ/TENOFOVIR DISOPROXIL FUMARATE/EMTRICITABINE, ELVITEGRAVIR & COBICISTAT & EMTRICITABINE & TENOFOVIR ALAFENAMIDE, EMTRICITABINE & RILPIVIRINE HCL & TENOFOVIR ALAFENAMIDE HEMIFUMARATE, EMTRICITABINE & RILPIVIRINE HCL & TENOFOVIR DISOPROXIL, EMTRICITABINE & TENOFOVIR DISOPROXIL FUMARATE, ETRAVIRINE, FOSAMPRENAVIR CALCIUM, GANCICLOVIR SODIUM, LAMIVUDINE & ZIDOVUDINE, LOPINAVIR & RITONAVIR, MARAVIROC, NELFINAVIR MESYLATE, RALTEGRAVIR POTASSIUM, RILPIVIRINE HYDROCHLORIDE, RITONAVIR Some products covered without a code (check the product listing): ACYCLOVIR, ATAZANAVIR SULFATE, DARUNAVIR, EFAVIRENZ, LAMIVUDINE, NEVIRAPINE, VALACYCLOVIR 08:18 Antivirals

ABACAVIR SULFATE

· 4 products · General benefit · strengths: 20mg/mL, 300mg · O/L, Tab

LAMIVUDINE

· 10 products · General benefit (7), Listed, not a benefit (1), Limited Use, codes 502, 503, 504 (2) · strengths: 10mg/mL, 100mg, 150mg, 300mg · O/L, Tab

ENTECAVIR

· 8 products · Limited Use, codes 505, 506, 507, 508 · strengths: 0.5mg · Tab

TENOFOVIR DISOPROXIL

· 11 products · Limited Use, codes 517, 518, 519, 520, 521, 522 · strengths: 300mg · Tab

ADEFOVIR DIPIVOXIL

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 10mg · Tab

ZIDOVUDINE

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 100mg · Cap

ABACAVIR & LAMIVUDINE & ZIDOVUDINE

· 2 products · General benefit · strengths: 300mg & 150mg & 300mg · Tab

ABACAVIR SULFATE & LAMIVUDINE

· 7 products · General benefit · strengths: 600mg & 300mg · Tab

ACYCLOVIR

· 15 products · Listed, not a benefit (2), General benefit (13) · strengths: 200mg, 400mg, 800mg · Tab

ATAZANAVIR SULFATE

· 12 products · General benefit (8), Off-Formulary Interchangeable, not an ODB benefit (4) · strengths: 150mg, 200mg, 300mg · Cap

BICTEGRAVIR SODIUM/EMTRICITABINE/TENOFOVIR ALAFENAMIDE HEMIFUMARATE

· 1 products · General benefit · strengths: 50mg & 200mg & 25mg · Tab

CABOTEGRAVIR

· 3 products · General benefit · strengths: 200mg/mL, 30mg · Inj Sol-ER Susp 3mL Vial Kit Pk, Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 08:18 and 42 more
Full class listing Related classes: 08:08 Anthelmintics, 08:12 Antibiotics, 08:14 Antifungals, 08:16 Antitubercular Agents, 08:20 Plasmodicides (Antimalarials), 08:24 Sulfonamides, 08:30 Antiprotozoals, 08:32 Trichomonacides, 08:36 Urinary Anti-Infectives, 08:40 Miscellaneous Anti-Infectives Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE VEMLIDY is indicated for the treatment of chronic hepatitis B in adults with compensated liver disease (see WARNINGS AND PRECAUTIONS). Geriatrics (≥ 65 years of age) Clinical trials of VEMLIDY did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients (see ACTION AND CLINICAL PHARMACOLOGY). Pediatrics (< 18 years of age) Safety and effectiveness of VEMLIDY in pediatric patients less than 18 years of age have not been established. https://pdf.hres.ca/dpd_pm/00058101.PDF PM date: August 20, 2020 Source product: VEMLIDY; DIN 02464241; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.